

# Are Women with Sjögren's Syndrome Androgen-Deficient?

DAVID A. SULLIVAN, ALAIN BÉLANGER, JENNIFER M. CERMAK, RENÉ BÉRUBÉ, ATHENA S. PAPAS, ROSE M. SULLIVAN, HIROKO YAMAGAMI, M. REZA DANA, and FERNAND LABRIE

**ABSTRACT. Objective.** We hypothesize that androgen deficiency is a critical etiologic factor in the pathogenesis of aqueous-deficient and evaporative dry eye in Sjögren's syndrome (SS). We investigated whether women with SS have a deficiency in total androgens. We also examined whether these patients have elevated serum concentrations of estrogens.

**Methods.** Blood was drawn from women with primary and secondary SS and age matched controls, and analyzed for steroid concentrations by gas and liquid chromatography-mass spectrometry.

**Results.** Our results show that women with SS are androgen-deficient. Concentrations of 5-androstene-3 $\beta$ ,17 $\beta$ -diol (5-diol), dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT), androsterone-glucuronide (ADT-G), and androstane-3 $\alpha$ ,17 $\beta$ -diol-G (3 $\alpha$ -diol-G) were all significantly reduced in SS sera relative to controls. In contrast, SS was not associated with significant alterations in the serum concentrations of testosterone, androstenedione, estrone, or 17 $\beta$ -estradiol. These overall findings could not be attributed to the use of oral contraceptives or hormone replacement therapy, because the concentrations of 5-diol, DHEA, DHT, ADT-G and 3 $\alpha$ -diol-G were also decreased in patients with SS compared to levels in control women who were not taking exogenous estrogens.

**Conclusion.** Our results show that women with SS are androgen-deficient. (J Rheumatol 2003; 30:2413-9)

## Key Indexing Terms:

SJÖGREN'S SYNDROME

ANDROGENS

ESTROGENS

DRY EYE

Sex steroid deficiency has been linked to the development and/or progression of a wide variety of clinical disorders, including insulin resistance, cardiovascular disease, obesity, osteoporosis, and certain cancers<sup>1</sup>. We hypothesize that sex steroid deficiency, particularly that of androgens, may also be a critical etiologic factor in the pathogenesis of dry eye syndromes. These syndromes, which afflict over 10 million Americans<sup>2</sup>, are classified into 2 major types: aqueous-deficient and evaporative<sup>3</sup>. Aqueous-deficient dry eye is due to

a lack of tear secretion by the lacrimal glands. An example is Sjögren's syndrome (SS), an autoimmune disease that occurs almost exclusively in women. This disorder is associated with extensive inflammation of lacrimal tissue, immune mediated destruction and/or dysfunction of acinar and ductal epithelial cells, and a precipitous decline in aqueous tear output<sup>4,5</sup>. SS may be either primary (i.e., no associated connective tissue disease) or secondary [e.g., patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)]. The second type of dry eye is called evaporative and is typically caused by meibomian gland dysfunction and lipid insufficiency, resulting in increased evaporation and decreased stability of the tear film<sup>6</sup>. This form of dry eye is also found in SS, as well as during menopause and aging<sup>7-9</sup>. It has been estimated that meibomian gland disease may be a contributing factor in over 60% of all patients with dry eye<sup>10</sup>.

The rationale for our hypothesis concerning androgen deficiency and dry eye syndromes is 2-fold. First, androgens regulate multiple aspects of the lacrimal gland, including epithelial cell morphology, gene expression, protein synthesis, secretory processes, and immune activity<sup>11</sup>. Moreover, serum concentrations of testosterone are reportedly decreased in patients with SS<sup>12</sup>, and this reduction may predispose to lacrimal gland dysfunction, reduced tear secretion, and dry eye. Consistent with this proposition is the finding that testosterone administration to female mouse models of SS (i.e., MRL/Mp-lpr/lpr and NZB/NZW F1)

From the Schepens Eye Research Institute, Harvard Medical School; Brigham and Women's Hospital; and Tufts University School of Dental Medicine, Boston, Massachusetts, USA; and Laboratory of Molecular Endocrinology, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada.

Supported by grants from Allergan, Inc., the Medical Research Council of Canada, and the Sjögren's Syndrome Foundation.

D.A. Sullivan, PhD, Schepens Eye Research Institute, Harvard Medical School; A. Bélangier, PhD, Centre Hospitalier Universitaire de Québec Research Center; J.M. Cermak, PhD, Schepens Eye Research Institute, Harvard Medical School, Brigham and Women's Hospital; R. Bérubé, MSc, Centre Hospitalier Universitaire de Québec Research Center; A.S. Papas, DMD, PhD, Tufts University School of Dental Medicine; R.M. Sullivan, RN, Schepens Eye Research Institute; H. Yamagami, MD, PhD, Schepens Eye Research Institute, Harvard Medical School; M.R. Dana, MD, MPH, Schepens Eye Research Institute, Harvard Medical School, Brigham and Women's Hospital; F. Labrie, MD, PhD, Centre Hospitalier Universitaire de Québec Research Center.

Address reprint requests to Dr. D.A. Sullivan, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114, USA.

E-mail: sullivan@vision.eri.harvard.edu

Submitted November 14, 2002; revision accepted March 2, 2003.

causes a dramatic suppression of the inflammation and a significant increase in the functional activity of lacrimal glands<sup>5,13</sup>. Similarly, androgen treatment has been reported to alleviate dry eye signs and symptoms, and stimulate tear flow, in patients with SS<sup>14-16</sup>. The second consideration is that androgens regulate meibomian gland function, enhance the quality and/or quantity of lipids produced by this tissue, and promote the formation of the tear film's lipid layer<sup>17</sup>. Conversely, androgen deficiency, such as occurs during menopause, aging, SS, complete androgen insensitivity syndrome (CAIS), and the use of anti-androgen therapy, is associated with meibomian gland dysfunction, altered lipid profiles in meibomian gland secretions, tear film instability, and evaporative dry eye<sup>17</sup>. Further, investigators have reported that low serum concentrations of testosterone are more prevalent in women with dry eye and correlate with the subjective severity of ocular symptoms<sup>18</sup>.

However, although these findings are consistent with our hypothesis concerning menopause, aging, CAIS, and the use of anti-androgen medication, they do not show a definitive link between androgen deficiency and dry eye syndromes in women with SS. The reason is that a previous study<sup>12</sup> focused primarily upon serum testosterone concentrations, which represent only a very small fraction of the total androgen pool in humans<sup>1,19-25</sup>. Indeed, it appears that the measurement of serum testosterone in women has little or no value except as an index of ovarian activity<sup>19,21,23</sup>, and this tissue is not the principal origin of androgens (or estrogens) in women<sup>19,21,23,25</sup>. As shown in the emerging field of intracrinology, the majority of androgens (e.g., 75% before and 100% after menopause) in women are synthesized in peripheral tissues from adrenal sex steroid precursors [i.e., dehydroepiandrosterone (DHEA), DHEA-sulfate (DHEA-S), and androstenedione]<sup>1,19,21-26</sup>. Indeed, humans and primates are unique in possessing adrenal glands that secrete large amounts of DHEA and DHEA-S, which are then converted into potent androgens (e.g., testosterone, DHT) and estrogens by steroidogenic enzymes in peripheral sites and thereby permit target tissues to adjust the formation and metabolism of sex steroids to local requirements<sup>21,25</sup>. This situation contrasts sharply with that in lower mammals (e.g., mice, rats, guinea pigs), in which the ovaries and testes are the exclusive source of active sex steroids<sup>1,21</sup>. Further, the most valid and perhaps the only reliable estimate of the total androgen pool in humans is the serum concentration of the conjugated DHT metabolites, such as androsterone-glucuronide (ADT-G) and androstane-3 $\alpha$ ,17 $\beta$ -diol-G (3 $\alpha$ -diol-G), which reflects the total intracrine production and metabolism of androgens in peripheral tissues throughout the body<sup>19,23,24</sup>. These levels have not been measured in women with either primary or secondary SS.

To further test our hypothesis, we sought to determine whether women with SS have a deficiency in total androgens, as indicated by the serum concentrations of androgen

precursors [i.e., DHEA, 5-androstene-3 $\beta$ ,17 $\beta$ -diol (5-diol), and androstenedione], active androgens [i.e., testosterone and dihydrotestosterone (DHT)], and their metabolites (i.e., ADT-G and 3 $\alpha$ -diol-G). For comparative purposes, we also examined whether these patients have elevated concentrations of circulating estrogens (i.e., estrone and 17 $\beta$ -estradiol). The levels of potent estrogens are known to be increased in SLE<sup>27</sup>, and may well predispose to the sex related incidence and development of SS<sup>28,29</sup>.

## MATERIALS AND METHODS


**Human subjects.** Women (age 53.1  $\pm$  2.9 yrs) with primary SS (n = 10;  $\geq$  4 European criteria<sup>30</sup>) and secondary SS (n = 12 SLE; n = 9 RA) were recruited from outpatient clinics at Brigham and Women's Hospital and Tufts University School of Dental Medicine, as well as from the Sjögren's Syndrome Foundation (Jericho, NY, USA). Patients with primary SS met the criteria established by the European Study Group<sup>30</sup> whereas women with SLE<sup>31</sup> and RA<sup>32</sup> fulfilled the criteria set by the American College of Rheumatology. Age and sex matched controls (n = 26, age 51.7  $\pm$  3.6 yrs), who had no history of autoimmune disease, were recruited from the Boston area and from The Harvard Cooperative Program on Aging (Boston, MA). After written informed consent was obtained, blood was drawn by phlebotomists in the Clinical Research Center at Brigham and Women's Hospital or Tufts University School of Dental Medicine. Samples were then processed for separation of serum and stored at -70°C until experimental analysis. These studies were approved by the Human Studies Committees of Brigham and Women's Hospital and Tufts University School of Dental Medicine, and were conducted in accordance with the Declaration of Helsinki.

**Measurement of steroid hormone concentrations in sera.** Serum steroid levels were measured as described by gas chromatography-mass spectrometry (DHEA, 5-diol, androstenedione, testosterone, DHT, estrone, and 17 $\beta$ -estradiol) using electron impact or chemical ionization, and by liquid chromatography-tandem mass spectrometry using a turboionspray (ADT-G and 3 $\alpha$ -diol-G)<sup>33-35</sup>. Briefly, steroids were extracted from serum by liquid-liquid and/or solid-phase extraction. Derivatization reactions were performed to improve chromatographic and detection response, with the exception of ADT-G. Interassay variations for these steroid measurements were as follows: DHEA 4.9%, 5-diol 5.9%, androstenedione 2.9%, testosterone 3.3%, DHT 1.9%, estrone 3.5%, 17 $\beta$ -estradiol 4.1%, ADT-G 2.9%, and 3 $\alpha$ -diol-G 3.7%. Repeat analyses of selected serum samples yielded identical results. Data were analyzed using the Mann-Whitney U test.

## RESULTS

As shown in Figure 1, our results show that SS is associated with significant alterations in the circulating concentrations of sex steroids. Concentrations of DHEA, 5-diol, DHT, ADT-G, and 3 $\alpha$ -diol-G were all significantly reduced in sera of patients with SS relative to those of controls. In contrast, SS was not associated with significant changes in the serum levels of androstenedione, testosterone, estrone, or 17 $\beta$ -estradiol (Figure 2).

These alterations in sex steroid levels in SS could not be attributed to oral contraceptive use, hormone replacement therapy (HRT), concurrent Hashimoto's thyroiditis, liver or kidney disease, corticosteroid treatment, or statin medications. The concentrations of DHEA, 5-diol, DHT, ADT-G, and 3 $\alpha$ -diol-G were also attenuated in SS patients (n = 15, age 54.5  $\pm$  4.9 yrs), compared to control women (n = 24, age




**Figure 1.** Influence of SS on serum concentrations of androgen precursors, hormones, and metabolites. Sera were obtained from women with primary or secondary SS (n = 31) and age matched controls (n = 26). Assay sensitivities for the steroids were as follows: DHEA 0.40 ng/ml, 5-diol 0.15 ng/ml, DHT 25 pg/ml, ADT-G 2.0 ng/ml, and 3 $\alpha$ -diol-G 0.5 ng/ml. If levels were below the limit of assay quantitation, values were recorded as zero. Columns and bars show the mean  $\pm$  SE. Significantly less than control: \*p < 0.05; <sup>†</sup>p < 0.005; <sup>‡</sup>p < 0.0005.

52.5  $\pm$  3.5 yrs) who were not taking exogenous estrogens (Figure 3). No differences between these subgroups were found in the levels of serum androstenedione, testosterone, estrone, or 17 $\beta$ -estradiol (Figure 4). Moreover, only one patient had Hashimoto's thyroiditis and one other had glomerulonephritis, and exclusion of these data did not change the significance of the results. No patient or control had liver disease.

Our finding of androgen deficiency in women with SS could also not be explained by the use of corticosteroids. Evaluation of data from subjects not undergoing corticosteroid therapy showed that the serum levels of DHEA and ADT-G were significantly reduced (p < 0.05) in women with SS (n = 14, age 57.1  $\pm$  4.3 yrs), compared to controls (n = 26, age 51.7  $\pm$  3.4 yrs). The mean serum concentration of 3 $\alpha$ -diol-G was also decreased by 32% (p < 0.087) in the SS group.

During the course of the study, 3 subjects were taking statin medications, including fluvastatin (control), simvastatin (primary SS), and lovastatin (secondary SS). Exclusion of these data from the analyses did not change the significance of any of the comparative results.



**Figure 2.** Influence of SS on serum concentrations of various androgens and estrogens. Sera were collected as described in the legend to Figure 1. Assay sensitivities for the steroids were as follows: androstenedione 0.25 ng/ml, testosterone 0.20 ng/ml, estrone 10 pg/ml, and 17 $\beta$ -estradiol 5.0 pg/ml. If levels were below the limit of assay quantitation, values were recorded as zero.

Lastly, it is unlikely that the androgen deficiency in SS could be explained by variations in sex steroid levels during the menstrual cycle. Menopause in the industrialized countries occurs at a median age of 51.4 years<sup>36</sup>, and we analyzed data from individuals who were 55 years and older and who were not taking estrogen supplementation. The serum concentrations of DHEA, 5-diol, DHT, ADT-G, and 3 $\alpha$ -diol-G were all still significantly (p < 0.05) decreased in women aged 55+ years with SS (n = 8, age 69.8  $\pm$  3.2 yrs) relative to controls (n = 12, age 66.3  $\pm$  2.7 yrs). The mean concentration of androstenedione was also attenuated by 76% (p < 0.0993) in patients with SS.

## DISCUSSION

Our results demonstrate that women with Sjögren's syndrome are androgen-deficient. Thus, the serum concentrations of DHEA, 5-diol, DHT, ADT-G, and 3 $\alpha$ -diol-G were significantly decreased in women with SS compared to controls. In contrast, SS was not associated with significant changes in the serum concentrations of testosterone, androstenedione, estrone, or 17 $\beta$ -estradiol. These findings support our hypothesis that an androgen deficiency exists in SS. This deficit, in turn, may be a critical etiologic factor in the pathogenesis of aqueous-deficient and evaporative dry eye in this disorder.

Our experimental observations are consistent with the findings of other investigators with regard to circulating androgen levels in primary SS, SLE, and RA. Primary SS is associated with a significant decrease in the serum level of




Figure 3. Effect of SS on serum levels of androgen precursors, hormones, and metabolites in women not taking exogenous estrogens. Sera were obtained from women with SS (n = 15) and age matched controls (n = 24) and processed for steroid analyses. Significantly less than control: \*p < 0.05; †p < 0.005.

DHEA-S, but not of testosterone or androstenedione<sup>37</sup>. Similarly, SLE and RA are accompanied by a significant reduction in circulating levels of DHEA<sup>38-44</sup>, DHEA-S<sup>38,39,43-46</sup>, and DHT<sup>38,42</sup>, whereas the concentrations of testosterone and androstenedione may be decreased, increased, or unchanged<sup>38,39,42,43,47</sup>. It is important that a primary focus of these previous investigations was on the levels of circulating DHEA and DHEA-S, which are precursors for potent androgens and estrogens. In contrast, our study evaluated the serum concentrations of a number of androgens, including ADT-G and 3α-diol-G. These glucuronidated DHT metabolites reflect the overall intracrine production and metabolism of androgens in peripheral tissues and appear to be the most reliable measure of the total androgen pool in humans<sup>19,23,24,48</sup>.

Interestingly, androgen deficiency may also contribute to the sex related prevalence of many autoimmune diseases. Thus, the incidence and/or severity of a number of autoimmune disorders are far greater in women compared to men<sup>49</sup>. This sexual dichotomy, in turn, has been linked in part to the differential actions of sex steroids on the immune system<sup>50-52</sup>. Estrogens often promote, whereas androgens frequently reduce, the progression of autoimmune sequelae<sup>5,50-58</sup>.




Figure 4. Influence of SS on serum concentrations of various androgens and estrogens in women not taking exogenous estrogens. Sera were processed as described in the legend to Figure 3.

Consequently, androgen insufficiency may predispose to the development of certain autoimmune states. This may explain why androgen therapy has been successful in ameliorating various signs and symptoms in animal models of SLE, thyroiditis, polyarthritis, autoimmune hemolytic anemia, and myasthenia gravis, as well as in humans with SLE and RA<sup>5,14,16,50-52,59-62</sup>.

The androgen deficiency in SS could not be attributed to the influence of oral contraceptive use, HRT, menstrual cycle fluctuations, corticosteroid therapy, or statin treatment. This finding is significant, because estrogens and statins may decrease concentrations of precursor and/or active androgens<sup>40,63</sup>, and the menstrual cycle is associated with variations in the concentrations of serum androgens<sup>64</sup>. In addition, corticosteroid administration is known to reduce circulating levels of DHEA<sup>40</sup> and testosterone<sup>42,46,65,66</sup>. It is possible in our investigation that corticosteroid therapy may have contributed to the attenuated levels of 5-diol and DHT in the SS group. The reason is that the serum concentrations of these hormones were analogous in the subsets of patients and controls who were not taking exogenous glucocorticoids.

The mechanism(s) by which a systemic androgen deficiency occurs in primary and secondary SS may involve genetic factors<sup>37</sup> and/or, as in RA, an adrenal gland abnormality in the elaboration of androgen precursors<sup>44,67</sup>. Another possibility is that an altered metabolism of sex steroids may occur in peripheral tissues. For example, in female patients with SLE both the oxidation of testosterone and the 16α-hydroxylation of estrone are increased, leading to an attenuated androgen/estrogen ratio and an enhanced

amount of circulating and potent estrogen metabolites<sup>27,53,68,69</sup>. Although serum levels of estrone and 17 $\beta$ -estradiol are not elevated in patients with SS, the concentrations of corresponding metabolites have yet to be measured. These analyses would be of particular interest, because estrogens may be involved in the etiology, progression, and/or amplification of SS<sup>28,29</sup>. These hormones may also enhance the polyclonal B cell activation, autoantibody formation, and tissue abnormalities encountered in this disorder<sup>28,29,70</sup>.

The possibility exists that even greater deficiencies in androgen content may occur in specific tissues in SS. For example, elevated levels of proinflammatory cytokines (e.g., interleukins 1 and 6 and tumor necrosis factor- $\alpha$ ) may disrupt the normal activity of steroidogenic enzymes and promote the aromatization of testosterone to 17 $\beta$ -estradiol<sup>71-73</sup>. Considering that expression of such cytokines is increased in the lacrimal gland and inflamed lids (i.e., meibomian gland environment) in SS<sup>74-76</sup>, and that the lacrimal and meibomian glands contain mRNA encoding the enzymes responsible for the intracrine synthesis and metabolism of active sex steroids<sup>77</sup>, cytokine action may suppress the local formation of androgens. Further, these cytokines may attenuate the expression of androgen receptor mRNA<sup>78</sup> and interfere with certain androgenic effects<sup>79</sup>. Consequently, the influence of androgens may be significantly compromised in these ocular tissues, predisposing to lacrimal and meibomian gland dysfunction and the associated aqueous-deficient and evaporative dry eye.

Overall, our findings demonstrate that women with Sjögren's syndrome are androgen-deficient. This deficit may contribute significantly to the development of dry eye syndrome in this disorder.

## ACKNOWLEDGMENT

The authors express their appreciation to Alexis Stegemann (Long Island, NY) and Dr. Mibi Singh (Boston, MA) for their assistance.

## REFERENCES

- Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation: Intracrinology. *Ann NY Acad Sci* 1995;774:16-28.
- Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. *Adv Exp Med Biol* 2002;506:989-98.
- Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. *CLAO J* 1995;21:221-32.
- Homma M, Sugai S, Tojo T, Miyasaka N, Akizuki M, editors. Sjögren's syndrome. State of the art. Amsterdam: Kugler Press; 1994.
- Sullivan DA, Wickham LA, Krenzer KL, Rocha EM, Toda I. Aqueous tear deficiency in Sjögren's syndrome: Possible causes and potential treatment. In: Pleyer U, Hartmann C, Sterry W, editors. *Oculodermatological diseases — Immunology of bullous oculo-muco-cutaneous disorders*. Buren, The Netherlands: Aeolus Press; 1997:95-152.
- Driver PJ, Lemp MA. Meibomian gland dysfunction. *Surv Ophthalmol* 1996;40:343-67.
- Krenzer KL, Cermak JM, Tolls DB, Papas AS, Dana MR, Sullivan DA. Comparative signs and symptoms of dry eye in primary and secondary Sjögren's syndrome and meibomian gland disease [abstract]. *Invest Ophthalmol Vis Sci* 1999;40:S2864.
- Nabata H, Horiuchi H, Miyata K, Tsuru T, Machinami R. Histopathological study of the human meibomian glands [abstract]. *Invest Ophthalmol Vis Sci* 1994;35 Suppl:1789.
- Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. *Cornea* 1992;11:334-42.
- Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. *Arch Ophthalmol* 1995;113:1266-70.
- Sullivan DA, Wickham LA, Rocha EM, Kelleher RS, Silveira LA, Toda I. Influence of gender, sex steroid hormones and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. *Adv Exp Med Biol* 1998;438:11-42.
- Xu G, Shang H, Zhu F. Measurement of serum testosterone level in female patients with dry eye [abstract]. *Proceedings of the International Congress of Ophthalmology Meeting; Toronto, Canada; 1994*.
- Sullivan DA, Edwards J. Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome. *J Ster Biochem Mol Biol* 1997;60:237-45.
- Bizzarro A, Valentini G, Di Marinto G, Daponte A, De Bellis A, Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. *J Clin Endocrinol Metab* 1987;64:32-6.
- Lagresa MNS, Suarez NM, Lescaille DV, Lagresa CMS. Inductores de lágrimas: Andrógenos y gammaglobulinas humanas. *Rev Cubana Oftalmol* 2000;13:35-43.
- Bruckner R. Über einem erfolgreich mit perandren behandelten fall von Sjogren'schem symptomem komplex. *Ophthalmologica* 1945;110:37-42.
- Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction and evaporative dry eye. *Ann NY Acad Sci* 2002;966:211-22.
- Mamalis N, Harrison DY, Hiura G, et al. Dry eyes and testosterone deficiency in women [abstract]. In: *Abstracts of the Centennial Annual Meeting of the American Academy of Ophthalmology 1996, Chicago, Illinois: 132*.
- Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 1997;82:2396-402.
- Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. *J Clin Endocrinol Metab* 1994;79:1086-90.
- Labrie F. Intracrinology. *Mol Cell Endocrinol* 1991;78:C113-8.
- Belanger A. Determination of non-conjugated and conjugated steroids in human plasma. In: Gorog S, editor. *Advances in steroid analysis '93: Proceedings from the 5th Symposium on the Analysis of Steroids, Szombathely, Hungary, May 3-5, 1993*. Budapest: Akademia Kiado; 1994:99-110.
- Labrie F, Bélanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. *J Clin Endocrinol Metab* 1997;82:2403-9.
- Labrie F, Diamond P, Cusan L, Gomez J-L, Bélanger A, Candas B. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997;82:3498-505.
- Labrie F, Bélanger A, Luu-The V, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging. *Steroids* 1998;63:322-8.
- Labrie F, Luu-The V, Lin SX, et al. The key role of 17 $\beta$ -hydroxysteroid dehydrogenases in sex steroid biology. *Steroids*

- 1997;62:148-58.
27. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 $\alpha$ -hydroxylation of estradiol in systemic lupus erythematosus. *J Clin Endocrinol Metab* 1981;53:174-8.
  28. Carlsten H, Tarkowski A, Holmdahl R, Nilsson LA. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. *Clin Exp Immunol* 1990;80:467-73.
  29. Ahmed SA, Aufdemorte TB, Chen JR, Montoya AI, Olive D, Talal N. Estrogen induces the development of autoantibodies and promotes salivary gland lymphoid infiltrates in normal mice. *J Autoimmunity* 1989;2:543-52.
  30. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European Classification Criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjogren's Syndrome. *Ann Rheum Dis* 1996;55:116-21.
  31. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
  32. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
  33. Berube R, Gauvin D, Blais M, Beaudoin J, Noreau L, Bélanger A. Determination of testosterone, 5-androstene-3 $\beta$ ,17 $\beta$ -diol, dehydroepiandrosterone and 4-androstenedione in human serum using high resolution gas chromatography and electron impact mass spectrometry [abstract]. Proceedings of the 47th ASMS Conference on Mass Spectrometry and Allied Topics; June 1999, Dallas, Texas.
  34. Berube R, Malenfant J, Gauvin D, et al. Quantitation of androgenic and estrogenic steroids in rat and monkey serum using gas chromatography and negative chemical ionization mass spectrometry [abstract]. Proceedings of the 48th ASMS Conference on Mass Spectrometry and Allied Topics; June 2000, Long Beach, California.
  35. Belanger P, Paradis D, Gagné D, Bérubé R, Bélanger A. Determination of androsterone glucuronide and androstane-3 $\alpha$ ,17 $\beta$ -diol glucuronide in human plasma by turbo ionspray LC-MS MS [abstract]. Proceedings of the 48th ASMS Conference on Mass Spectrometry and Allied Topics; June 2000, Long Beach, California.
  36. Council of Affiliated Menopause Societies, International Menopause Society. Menopause core curriculum study guide. [cited June 10, 2003] Website: [www.menopause.org/edumaterials/studyguide/studyguide.html](http://www.menopause.org/edumaterials/studyguide/studyguide.html)
  37. Valtysdottir ST, Wide L, Hällgren B. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. *J Rheumatol* 2001;28:1259-65.
  38. Jungers P, Khalil N, Pelissier C, Cougados M, Tron F, Bach J-F. Low plasma androgens in women with active or quiescent systemic lupus erythematosus. *Arthritis Rheum* 1982;25:454-7.
  39. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. *Arthritis Rheum* 1987;30:241-8.
  40. Derksen RH. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. *Semin Arthritis Rheum* 1998;27:335-47.
  41. Masi AT, Josipovic DB, Jefferson WE. Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): Gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion. *Semin Arthritis Rheum* 1984;14:1-23.
  42. Cutolo M, Masi AT. Do androgens influence the pathophysiology of rheumatoid arthritis? Facts and hypotheses [editorial]. *J Rheumatol* 1998;25:1041-7.
  43. Cutolo M, Foppiani L, Prete C, et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. *J Rheumatol* 1999;26:282-8.
  44. Masi AT, Bijlsma JW, Chikanza IC, Pitzalis C, Cutolo M. Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. *Semin Arthritis Rheum* 1999;29:65-81.
  45. Feher KG, Feher T. Plasma dehydroepiandrosterone, dehydroepiandrosterone sulphate and androsterone sulphate levels and their interaction with plasma proteins in rheumatoid arthritis. *Exp Clin Endocrinol* 1984;84:197-202.
  46. Sambrook PN, Eisman JA, Champion GD, Pocock NA. Sex hormone status in postmenopausal women with rheumatoid arthritis. *Arthritis Rheum* 1988;31:973-8.
  47. Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status in women suffering from rheumatoid arthritis. *J Rheumatol* 1986;13:1012-23.
  48. Hum DW, Belanger A, Levesque E, et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. *J Steroid Biochem Mol Biol* 1999;69:413-23.
  49. Beeson PB. Age and sex associations of 40 autoimmune diseases. *Am J Med* 1994;96:457-62.
  50. Ahmed SA, Penhale WJ, Talal N. Sex hormones, immune responses and autoimmune diseases. *Am J Pathol* 1985;121:531-51.
  51. Homo-Delarche F, Fitzpatrick F, Christeff N, Nunez EA, Bach JF, Dardenne M. Sex steroids, glucocorticoids, stress and autoimmunity. *J Ster Biochem Mol Biol* 1991;40:619-37.
  52. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. *Endocr Rev* 1996;17:369-84.
  53. Cutolo M, Sulli A, Seriola B, Masi AT. Estrogens, the immune response and autoimmunity. *Clin Exp Rheumatol* 1995;13:217-26.
  54. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Arthritis Rheum* 1999;42:328-37.
  55. Kanda N, Tsuchida T, Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1703-11.
  56. Jansson L, Holmdahl R. Estrogen-mediated immunosuppression in autoimmune diseases. *Inflamm Res* 1998;47:290-301.
  57. Araneo BA, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and  $\gamma$ -interferon, but not IL-2 by activated murine T cells. *Blood* 1991;78:688-99.
  58. Li ZG, Danis VA, Brooks PM. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. *Clin Exp Rheumatol* 1993;11:157-62.
  59. Harbuz MS, Perveen-Gill Z, Lightman SL, Jessop DS. A protective role for testosterone in adjuvant-induced arthritis. *Br J Rheumatol* 1995;34:1117-22.
  60. Appelmans M. La Kerato-conjonctivite seche de Gougerot-Sjogren. *Arch Ophthalmologie* 1948;81:577-88.
  61. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiopathic manipulation. *Ann Rheum Dis* 1997;56:5-11.
  62. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. *Arthritis Rheum* 1991;34:1-5.
  63. 2002 Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co.; 2002.
  64. Rebar RW. Practical evaluation of hormonal status. In: Yen SSC, Jaffe RB, Barbieri RL, editors. *Reproductive endocrinology*:

- physiology, pathophysiology, and clinical management. Philadelphia: WB Saunders Company; 1999:709-47.
65. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. *J Clin Endocrinol Metab* 1976;43:622-9.
  66. Navarro MA, Nolla JM, Machuca MI, et al. Salivary testosterone in postmenopausal women with rheumatoid arthritis. *J Rheumatol* 1998;25:1059-62.
  67. Schuurs AHWM, Verheul HAM. Effects of gender and sex steroids on the immune response. *J Steroid Biochem* 1990;35:157-72.
  68. Lahita RG. The connective tissue diseases and the overall influence of gender. *Int J Fertil* 1996;41:156-65.
  69. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. *Arthritis Rheum* 1979;22:1195-8.
  70. Sato EH, Sullivan DA. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome. *Invest Ophthalmol Vis Sci* 1994;35:2632-42.
  71. Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. *J Clin Endocrinol Metab* 1995;80:3052-8.
  72. Macdiarmid F, Wang D, Duncan LJ, Purohit A, Ghilchick MW, Reed MJ. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. *Mol Cell Endocrinol* 1994;106:17-21.
  73. Nestler JE. Interleukin-1 stimulates the aromatase activity of human placental cytotrophoblasts. *Endocrinol* 1993;132:566-70.
  74. Rocha EM, Wickham LA, Huang Z, et al. Presence and testosterone influence on the levels of anti- and pro-inflammatory cytokines in lacrimal tissues of a mouse model of Sjögren's syndrome. *Adv Exp Med Biol* 1998;438:485-91.
  75. Robinson CP, Cornelius J, Bounous DE, Yamamoto H, Humphreys-Beher MG, Peck AB. Characterization of the changing lymphocyte populations and cytokine expression in the exocrine tissues of autoimmune NOD mice. *Autoimmunity* 1998;27:29-44.
  76. Jones DT, Monroy D, Ji Z, Pflugfelder SC. Alterations of ocular surface gene expression in Sjögren's syndrome. *Adv Exp Med Biol* 1998;438:533-6.
  77. Schirra F, Suzuki T, Dickinson D, Townsend DJ, Gipson IK, Sullivan DA. Presence of steroidogenic enzyme mRNAs in human lacrimal and meibomian glands, as well as corneal and conjunctival epithelial cells [abstract]. Abstracts of the European Association for Vision and Eye Research Meeting 2002; Alicante, Spain.
  78. Sokoloff MH, Tso CL, Kaboo R, et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. *Cancer* 1996;77:1862-72.
  79. Blais Y, Sugimoto K, Carriere MC, Haagensen DE, Labrie F, Simard J. Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on a polipoprotein D and GCDFP-15 expression in human breast cancer cells. *Int J Cancer* 1995;62:732-7.